Artificial Intelligence Use in Interventional Clinical Trials Registered on ClinicalTrials.gov - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Artificial Intelligence in Interventional Trials Registered at ClinicalTrials.gov

  • By

  • Selen Bozkurt

  • Irem Kar

  • Sweta Balaji

  • Nevruz Ilhanli

  • Selvi Ramalingam

  • Azra Ismail

  • Ravi B. Parikh

  • November 9, 2026

Share

  • 1

    The analysis included 1212 interventional trials registered on ClinicalTrials.gov with start dates from January 2022 onward and confirmed AI involvement.

  • 2

    Cancer was the leading clinical condition (20.0%), and screening or predictive modeling for disease risk or treatment selection was the most frequent AI application (39.8%).

  • 3

    Generative AI was planned in 166 trials (13.7%); its use rose from none of the trials initiated in 2022 to 100 of 491 (20.4%) initiated in 2025.

  • 4

    Images and video were the most common data modality (29.2%), and 69.3% of trials were single-site.

  • 5

    Although all included records described AI or machine learning, specific methods were often missing, and registry text documented intended rather than confirmed AI use.

Original Source(s)

Artificial Intelligence Use in Interventional Clinical Trials Registered on ClinicalTrials.gov

  • by Selen Bozkurt, Irem Kar, Sweta Balaji, Nevruz Ilhanli, Selvi Ramalingam, Azra Ismail, Ravi B. Parikh

  • November 9, 2026

Related Content

Monthly fasting cycles may be feasible in T2D

Nearly 1 in 3 participants discontinued the yearlong dietary program because of diet-related challenges, despite a 61% completion rate.

Can patient factors identify who benefits from fusion?

Investigators found no clear advantage across 6 prespecified patient characteristics, with fusion associated with more perioperative complications.

FDA approves first factor XIa stroke drug

In a 12,327-patient trial, asundexian cut recurrent ischemic stroke risk by 26% alongside antiplatelets.